Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome. outcome after 6 months of treatment with ospemifene

Aim of this study was to evaluate the efficacy of ospemifene in the prevention of recurrent lower urinary tract infections in postmenopausal women with vulvovaginal atrophy. The study have a retrospective design. Thirty-nine patients were enrolled. Patients underwent clinical examination and urine culture. The urinary symptoms and the quality of life were evaluated with UTISA score, PUF and SF-36 questionnaires before and after treatment. All 39 patients received ospemifene 60mg one tablet/daily for 6months. Adverse effects and complications were assessed. Thirty-nine patients were enrolled in the study. Two patients experienced one new UTI episode and the mean number of positive urine culture decreased significantly after 6months (3.652.12 vs 0.25 +/- 0.17, p<.0001). The mean number of urinary infection symptoms decreased significantly after treatment; dysuria reduced (4.76 +/- 2.45 vs 0.89 +/- 1.12). PUF score and SF-36 showed a statistically significant change (22.43 +/- 5.89 vs 12.14 +/- 3.21) and (52.86 +/- 9.21 vs 83.43 +/- 10.76). No adverse effects were reported and the total success rate was the 92.3% after 6months at PGI-I. Ospemifene is a valid alternative with excellent tolerability for the UTIS prevention in postmenopausal patients..